• [Show abstract] [Hide abstract]
    ABSTRACT: The levels of polybrominated diphenyl ethers (PBDEs) and indicator polychlorinated biphenyls (PCBs) were determined in marine fish from four areas of China (South China Sea, Bohai Sea, East China Sea, and Yellow Sea) using GC/NCI-MS and GC/ITMS, respectively. Total concentrations of eight PBDEs (BDE-28, 47, 99, 100, 153, 154, 183 and 209) in all samples ranged from 0.3ngg(-1)ww (wet weight) to 700 ng g(-1)ww, with median and mean values of 85 ng g(-1)ww and 200 ng g(-1)ww, respectively. BDE-209 and BDE-47 were the major congeners in all samples, contributing 54% and 19% to the total concentration, respectively. The sum of seven indicator PCB levels (CB-28, 52, 101, 118, 138, 153, and 180) ranged from 0.3 ng g(-1)ww to 3.1 μg g(-1)ww, with median and mean values of 6.4 ng g(-1)ww and 398 ng g(-1)ww, respectively. High contributions of CB-138 (32%) and CB-153 (25%) were found in all samples. In general, pollutants measured in this study were at high levels when compared with previous studies from other regions in the world. The relative abundance of BDE-209 may suggest that deca-BDE sources existed in studied area. And principal component analysis (PCA) showed that there were other PBDE sources in Yellow Sea. The pattern and PCA showed that PCB pollutions came from similar sources in the studied areas. In addition, concentrations of ∑(7)PBDEs (u/209) were strongly correlated with those of ∑(7)PCBs in all fish (r=0.907, n=44).
    Chemosphere 01/2011; 83(2):168-74. · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Memantine, a non-competitive NMDA receptor antagonist approved for Alzheimer's disease with a good safety profile, is increasingly being studied in a variety of non-dementia psychiatric disorders. We aimed to critically review relevant literature on the use of the drug in such disorders. We performed a PubMed search of the effects of memantine in animal models of psychiatric disorders and its effects in human studies of specific psychiatric disorders. The bulk of the data relates to the effects of memantine in major depressive disorder and schizophrenia, although more recent studies have provided data on the use of the drug in bipolar disorder as an add-on. Despite interesting preclinical data, results in major depression are not encouraging. Animal studies investigating the possible usefulness of memantine in schizophrenia are controversial; however, interesting findings were obtained in open studies of schizophrenia, but negative placebo-controlled, double-blind studies cast doubt on their validity. The effects of memantine in anxiety disorders have been poorly investigated, but data indicate that the use of the drug in obsessive-compulsive disorder and post-traumatic stress disorder holds promise, while findings relating to generalized anxiety disorder are rather disappointing. Results in eating disorders, catatonia, impulse control disorders (pathological gambling), substance and alcohol abuse/dependence, and attention-deficit hyperactivity disorder are inconclusive. In most psychiatric non-Alzheimer's disease conditions, the clinical data fail to support the usefulness of memantine as monotherapy or add-on treatment However, recent preclinical and clinical findings suggest that add-on memantine may show antimanic and mood-stabilizing effects in treatment-resistant bipolar disorder.
    CNS Drugs 08/2012; 26(8):663-90. · 4.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Based on the glutamatergic NMDA receptor hypofunction theory of schizophrenia, NMDA receptor modulators (NMDARMs) may have therapeutic potential in the treatment of schizophrenia. This meta-analysis aimed to evaluate the potential of modulators of the NMDA receptor as adjunctive therapy for schizophrenia, using the results from published trials. A primary electronic search for controlled clinical trials using NMDARMs in schizophrenia was conducted on the PubMed, Cochrane Library, EMBASE, CINAHL® and PsycINFO databases. A secondary manual search of references from primary publications was also performed. Inclusion criteria were the application of an established method of diagnosis, randomized case assignment, comparison of NMDARM add-on therapy with placebo, and double-blind assessment of symptoms in chronic schizophrenia using standardized rating scales. Results were based on a total sample size of 1253 cases from 29 trials that fulfilled the specified criteria. Scores on rating scales or on their relevant subscales were obtained for all selected studies from published results for the minimum dataset to compute the difference between post- and pre-trial scores and their pooled standard deviation for NMDARM add-on therapy and placebo groups for negative, positive and total symptoms. A negative standardized mean difference (SMD) indicates therapeutic benefit in favour of NMDARM add-on therapy and all SMD results mentioned here are statistically significant. The overall effect size for NMDARMs as a group was small for negative (SMD -0.27) and medium for total (SMD -0.40) symptoms of chronic schizophrenia. Subgroup analysis revealed medium effect sizes for D-serine and N-acetyl-cysteine (NAC) for negative (SMD -0.53 and -0.45, respectively) and total (SMD -0.40 and -0.64, respectively) symptoms, and for glycine (SMD -0.66) and sarcosine (SMD -0.41) for total symptoms. As adjuvants to non-clozapine antipsychotics, additional therapeutic benefits were observed for NMDARM as a group (SMD -0.14) and glycine (SMD -0.54) for positive symptoms; D-serine (SMD -0.54), NAC (SMD -0.45) and sarcosine (SMD -0.39) for negative symptoms; and NMDARM as a group (SMD -0.38), D-serine (SMD -0.40), glycine (SMD -1.12), NAC (SMD -0.64) and sarcosine (SMD -0.53) for total symptoms. When added to clozapine, none of the drugs demonstrated therapeutic potential, while addition of glycine (SMD +0.56) worsened positive symptoms. Taking into consideration the number of trials and sample size in subgroup analyses, D-serine, NAC and sarcosine as adjuncts to non-clozapine antipsychotics have therapeutic benefit in the treatment of negative and total symptoms of chronic schizophrenia. While glycine improves positive and total symptoms as an adjuvant to non-clozapine antipsychotics, it worsens them when added to clozapine.
    CNS Drugs 10/2011; 25(10):859-85. · 4.38 Impact Factor

Full-text

View
7 Downloads
Available from
Jun 3, 2014